Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials

BACKGROUND AND OBJECTIVES: Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor being developed as an orally administered treatment for patients with moderate to severe rheumatoid arthritis (RA) and other autoimmune disorders. These analyses characterized the population pharmacokinetics of upa...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Pharmacokinet
Huvudupphovsmän: Klünder, Ben, Mittapalli, Rajendar K., Mohamed, Mohamed-Eslam F., Friedel, Anna, Noertersheuser, Peter, Othman, Ahmed A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer International Publishing 2019
Ämnen:
Original Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6614152/
https://ncbi.nlm.nih.gov/pubmed/30945116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-019-00739-3
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk